Longitudinal Analysis of Candida Antifungal Susceptibility and Epidemiological Shifts at a Jordanian Tertiary Hospital (2019–2024)
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Fungal infections from Candida species pose a clinical threat due to changing distributions and emerging resistance. Shifts in species, antifungal susceptibility and factors associated with length of hospital stay were studied at a tertiary hospital in Jordan from 2019 to 2024. Methods: A retrospective study analyzed microbiology records at Jordan University Hospital. Isolates were identified with CHROMagar Candida and automated Vitek 2 Compact System. Antifungal susceptibility testing (AST) was CLSI M60-based. Mucosal colonization in non-blood specimens was excluded from clinical criteria. Amphotericin B activity was assessed against Epidemiological Cutoff Values (ECVs) of CLSI M60 and azole Susceptible-Dose-Dependent (S-DD) categories were examined explicitly. Trends before the COVID-19 pandemic and after the pandemic were analyzed using denominator-adjusted species proportions. Results: A total of 182 clinical isolates were analyzed. C. albicans (53.8%) dominated, followed by non-albicans Candida (NAC) species (especially C. glabrata [23.1%]). Voriconazole was the most susceptible (92.9%), while fluconazole showed the lowest susceptibility (63.7%), influenced by resistance in C. krusei (100% resistant) and low susceptibility in C. glabrata (2.4% S-DD). Amphotericin B Wild-Type (WT) profile rate is 91.2% (166/182 isolates; MIC ≤ 2.0 ug/mL per CLSI M60 ECVs), whereas C. glabrata showed an automated resistance signal to caspofungin, with 76.2% having an MIC ≥ 0.5 µg/mL, representing an automated screening signal requiring confirmatory reference broth microdilution testing. Species proportions changed significantly across COVID-19 periods (p < 0.001): C. albicans predominated during the pandemic (70.9%), whereas NAC species extended post-pandemic. Multivariable logistic regression identified patient’s age to be a predictor of hospital length of stay (LOS) ≥ 21 days (OR = 0.982, 95% CI: 0.971–0.993, p = 0.001). Conclusions: C. glabrata showed significant resistance to conventional azoles in Jordan. Automated echinocandin resistance signals need confirmatory reference testing before updating clinical guidelines. Standardized clinical infection criteria, routine AST, and institutional antifungal stewardship programs are robust in tertiary hospitals in Jordan.
Source: Pharmacoepidemiology
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: Candida, antifungal susceptibility, Candida albicans, Candida glabrata, non-albicans Candida, epidemiological cut-off values, amphotericin B resistance, voriconazole, fluconazole, caspofungin, azole resistance, COVID-19 pandemic, species distribution, length of hospital stay, fungemia, echinocandins
Open Access status: gold
Estimated APC paid: $1,207
OpenAlex ID: W7236586486
